Harmony Biosciences (NASDAQ:HRMY - Get Free Report)'s stock had its "hold (c-)" rating reiterated by investment analysts at Weiss Ratings in a research note issued to investors on Tuesday,Weiss Ratings reports.
Several other equities analysts also recently weighed in on the company. The Goldman Sachs Group initiated coverage on Harmony Biosciences in a research report on Thursday, July 10th. They issued a "neutral" rating and a $33.00 target price for the company. Truist Financial initiated coverage on Harmony Biosciences in a research report on Monday, July 21st. They issued a "buy" rating and a $48.00 target price for the company. Deutsche Bank Aktiengesellschaft dropped their target price on Harmony Biosciences from $54.00 to $36.00 and set a "buy" rating for the company in a research report on Thursday, September 25th. Wall Street Zen raised Harmony Biosciences from a "hold" rating to a "buy" rating in a research report on Saturday. Finally, Mizuho lowered their price objective on Harmony Biosciences from $50.00 to $35.00 and set an "outperform" rating for the company in a research report on Thursday, September 25th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, Harmony Biosciences has a consensus rating of "Moderate Buy" and a consensus price target of $46.11.
Check Out Our Latest Report on Harmony Biosciences
Harmony Biosciences Trading Up 0.7%
Shares of NASDAQ:HRMY traded up $0.18 during midday trading on Tuesday, reaching $26.54. 302,215 shares of the company's stock were exchanged, compared to its average volume of 703,561. The firm's 50 day simple moving average is $32.94 and its two-hundred day simple moving average is $32.83. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.84 and a quick ratio of 3.80. The stock has a market cap of $1.53 billion, a price-to-earnings ratio of 8.56, a P/E/G ratio of 0.33 and a beta of 0.79. Harmony Biosciences has a fifty-two week low of $25.95 and a fifty-two week high of $41.61.
Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $0.68 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.78 by ($0.10). The business had revenue of $200.49 million for the quarter, compared to analyst estimates of $204.37 million. Harmony Biosciences had a return on equity of 26.34% and a net margin of 23.44%.The firm's revenue for the quarter was up 16.0% compared to the same quarter last year. During the same period in the previous year, the business posted $1.05 earnings per share. Harmony Biosciences has set its FY 2025 guidance at EPS. As a group, sell-side analysts forecast that Harmony Biosciences will post 2.43 EPS for the current fiscal year.
Hedge Funds Weigh In On Harmony Biosciences
A number of institutional investors and hedge funds have recently added to or reduced their stakes in HRMY. Brooklyn Investment Group boosted its holdings in Harmony Biosciences by 1,031.9% in the first quarter. Brooklyn Investment Group now owns 1,064 shares of the company's stock valued at $35,000 after purchasing an additional 970 shares in the last quarter. Parkside Financial Bank & Trust boosted its holdings in Harmony Biosciences by 4,185.2% in the second quarter. Parkside Financial Bank & Trust now owns 1,157 shares of the company's stock valued at $37,000 after purchasing an additional 1,130 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in Harmony Biosciences in the first quarter valued at approximately $57,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Harmony Biosciences by 15.6% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,218 shares of the company's stock valued at $70,000 after purchasing an additional 299 shares in the last quarter. Finally, CWM LLC boosted its holdings in Harmony Biosciences by 34.8% in the first quarter. CWM LLC now owns 2,704 shares of the company's stock valued at $90,000 after purchasing an additional 698 shares in the last quarter. 86.23% of the stock is owned by institutional investors and hedge funds.
About Harmony Biosciences
(
Get Free Report)
Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Harmony Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harmony Biosciences wasn't on the list.
While Harmony Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
